Ocular Hypertension: all 659 studies

Page 7 of 7. Open to participants first (48), then studies with results posted, then the rest; newest registration first within each.

• Relationship Between Central Corneal Thickness and Intraocular Pressure Measures Instruments.CompletedNCT00347191
• Distribution of Risk Factors in Ocular Hypertension and Open-Angle Glaucoma Patients in CanadaCompletedNCT00334750
• A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular HypertensionCompletedNCT00333125Phase 3
• Safety and Efficacy Study of Bimatoprost/Timolol Fixed Combination in Patients With Glaucoma or Ocular HypertensionCompletedNCT00332540Phase 3
• Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular HypertensionCompletedNCT00332436Phase 3
• Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular HypertensionCompletedNCT00332384Phase 3
• Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular HypertensionCompletedNCT00332345Phase 2
• Safety and Efficacy Study of Bimatoprost/Timolol Fixed Combination in Patients Wtih Glaucoma or Ocular HypertensionCompletedNCT00332072Phase 3
• Safety and Efficacy Study of Bimatoprost/Timolol Fixed Combination in Patients With Glaucoma or Ocular HypertensionCompletedNCT00332059Phase 3
• 24-Hour Intraocular Pressure (IOP) And Blood Pressure Control In Glaucoma And Ocular Hypertension PatientsCompletedNCT00330577Phase 4
• An Evaluation of Use of Topical Ocular Hypotensive Medication by ComplianceCompletedNCT00329095Phase 4
• A Study of a Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular HypertensionCompletedNCT00326092Phase 2
• A Study of a Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular HypertensionCompletedNCT00314171Phase 3
• A Study of a Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular HypertensionCompletedNCT00314158Phase 3
• A 12-Month Study to Evaluate the Efficacy and Safety of Once-Daily Instillation of Combination Glaucoma Therapy in Patients With Open-Angle Glaucoma or Ocular HypertensionCompletedNCT00311389Phase 3
• Acupuncture for Elevated Intraocular PressureTerminatedNCT00307918Phase 3
• Latanoprost Versus FotilCompletedNCT00304785Phase 4
• Safety and Efficacy Study of Bimatoprost in Patients With Glaucoma or Ocular HypertensionCompletedNCT00300443Phase 2/3
• Study of the Intraocular Pressure (IOP)-Lowering Efficacy of Azopt 1.0% Compared to Timolol 0.5% in Patients With Glaucoma or Ocular HypertensionCompletedNCT00300079Phase 4
• A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular HypertensionCompletedNCT00293800Phase 3
• A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular HypertensionCompletedNCT00293787Phase 3
• A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular HypertensionCompletedNCT00293761Phase 3
• Phase III Safety and Efficacy Study to Evaluate a Glaucoma Therapy in Open-Angle Glaucoma or Ocular Hypertension PatientsCompletedNCT00288951Phase 3
• A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular HypertensionCompletedNCT00287521Phase 2
• Safety And Efficacy Of Xalatan Delivered Using Either A Conventional Dropper Bottle or A Delivery DeviceWithdrawnNCT00283764Phase 3
• A 12-week, Randomized, Double-masked, Parallel Group Comparison of Evening Dosing With Xalacom in Subjects With GlaucomaCompletedNCT00277498Phase 3
• Effects of Common Topical Glaucoma Therapy on Optic Nerve Head Blood Flow Autoregulation During Increased Arterial Blood Pressure and Artificially Elevated Intraocular Pressure in Healthy HumansWithdrawnNCT00275756Not applicable
• Cosopt Versus XalacomCompletedNCT00273481Phase 4
• Assessing Cosopt Switch PatientsCompletedNCT00273442Phase 4
• Cosopt Versus XalatanCompletedNCT00273429Phase 4
• Determination Of Predictive Factors Allowing To An Additional 10% Reduction Of Intra-Ocular PressureCompletedNCT00230763Phase 3
• Xalacom And Combination Of Unfixed Latanoprost And Timolol In Subjects With Open-Angle Glaucoma Or Ocular HypertensionCompletedNCT00219596Phase 3
• Safety and Efficacy of Brimonidine in Patients With Glaucoma or Ocular HypertensionCompletedNCT00168363Phase 3
• A 12-Week, Randomized, Double-Masked, Parallel Group Comparison Of Evening Dosing With Xalacom In Subjects With GlaucomaCompletedNCT00159653Phase 3
• A 5-Year Postmarketing Safety Study Of Xalcom In Patients With Open Angle Glaucoma Or Ocular HypertensionCompletedNCT00150267Phase 3
• Corneal Versus Conjunctival Delivery Using a Delivery DeviceWithdrawnNCT00143429Phase 2
• Evaluation Of Intraocular Pressure Lowering-Effect Of Xalacom In Patients With Poag Or Oh.CompletedNCT00143208Phase 4
• Efficacy And Safety Of Xalatan Compared To Usual Care In Patients With Open Angle Glaucoma Or Ocular Hypertension.CompletedNCT00140062Phase 4
• A 12week, Randomized, Evaluator-Masked, Parallel Group Comparing Evening Dosing Of Xalacom Vs Cosopt In Subj W/ GlaucomaCompletedNCT00140049Phase 4
• Additivity Study: Additive Effect on Eye Pressure of Azopt and Alphagan P to TravatanCompletedNCT00121147Not applicable
• Comparison of the Effects of Two Glaucoma Drugs Over 24 Hours (0507A-137)(COMPLETED)CompletedNCT00108017Phase 3
• Phase II Safety and Efficacy Study to Evaluate a Glaucoma Therapy in Open-Angle Glaucoma or Ocular Hypertension PatientsCompletedNCT00069719Phase 2
• Phase II Safety and Efficacy Study to Evaluate a Glaucoma Therapy in Open-angle Glaucoma or Ocular Hypertension PatientsCompletedNCT00069706Phase 2
• Safety and Efficacy Study of BETOPTIC S 0.25% and Timolol Gel-forming Solution 0.25% and 0.5% in Pediatric Patients With Glaucoma or Ocular HypertensionCompletedNCT00061542Phase 3
• A Phase III Study of Brimonidine Tartrate Ophthalmic Solution, 0.15% in Patients With Open-Angle Glaucoma or Ocular HypertensionCompletedNCT00061529Phase 3
• Safety and Efficacy Study of BETAXON 0.5% and AZOPT 1.0% in Pediatric Patients With Glaucoma or Ocular HypertensionCompletedNCT00061516Phase 3
• Mechanism of Action of TRAVATAN 0.004% in Subjects With Glaucoma or Ocular HypertensionCompletedNCT00061503Phase 4
• A 6-week Safety & Efficacy Study of Combination Intraocular Pressure-lowering Therapy in Patients With Open-angle Glaucoma or Ocular HypertensionCompletedNCT00051194Phase 2
• A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Chronic Angle-Closure GlaucomaCompletedNCT00051181Phase 3
• A 6-Week Safety and Efficacy Study of Travatan Compared to Xalcom in Subjects With Open-Angle Glaucoma(OAG) or Ocular Hypertension(OHT)CompletedNCT00051155Phase 3
• A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Open-Angle Glaucoma (OAG) or Ocular Hypertension (OHT)CompletedNCT00051142Phase 3
• Phase 4 Study Comparing IOP Lowering in OAG or OH in Caucasian or Japanese Subjects C-02-32TerminatedNCT00047606Phase 4
• Phase 3 Study Comparing IOP Lowering in OAG or OH in Japanese Subjects C-01-98CompletedNCT00047593Phase 3
• Study of TRAVATAN in Subjects With Iris Pigmentation ChangesTerminatedNCT00047554
• Phase 3 Study to Evaluate IOP Lowering Therapy in Open Angle Glaucoma and Ocular Hypertension C-01-70CompletedNCT00047541Phase 3
• Phase 3 Study to Evaluate IOP Lowering Therapy in Open Angle Glaucoma and Ocular Hypertension C-02-41CompletedNCT00047528Phase 3
• Phase 3 Study to Evaluate IOP Lowering Therapy in Open Angle Glaucoma and Ocular Hypertension C-01-69CompletedNCT00047515Phase 3
• Abnormalities of the Eye's Anterior Chamber, Iris, Cornea and LensCompletedNCT00001161
• Pigment Dispersion Syndrome With and Without GlaucomaCompletedNCT00001152

← Ocular Hypertension overview